Business Context and Reporting Period
This Form 8-K Current Report was filed by Pavmed Inc. on March 15, 2019, with the latest event date of March 20, 2019. The company is an emerging growth company incorporated in Delaware. The filing primarily addresses executive leadership changes, amendments to employment agreements, and a temporary modification to the conversion terms of a senior secured convertible note.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. However, it discloses specific capital structure details:
- Debt Instrument: A Senior Secured Convertible Note with an initial principal amount of $7,750,000 was issued in a private placement on December 27, 2018.
- Initial Conversion Price: $1.60 per share.
- Temporary Conversion Price Reduction: For a 21-day period (March 20, 2019, to April 9, 2019), the conversion price is reduced to the greater of $1.00 or the closing sale price of the common stock on the most recent trading day.
- Conversion Cap: The holder may convert no more than 1,000,000 shares at the reduced price.
Material Changes and Executive Actions
Significant corporate governance and compensation changes occurred on March 15, 2019:
- Executive Appointment: Dennis M. McGrath was appointed President while continuing to serve as Chief Financial Officer and Corporate Secretary.
- Employment Agreement Amendments: Agreements for CEO Lishan Aklog, M.D., and President Dennis M. McGrath were amended and restated with the following key terms:
- Term Extension: Extended to March 15, 2022, with automatic one-year renewals unless notice is given 60 days prior.
- Equity Grants: Dr. Aklog received 200,000 restricted shares; Mr. McGrath received 500,000 restricted shares. Vesting occurs in three equal annual installments starting March 15, 2020.
- Termination Benefits: Severance for termination without "cause" or for "good reason" is set at 12 months of base salary (24 months if within 60 days of a change of control). This replaces a previous provision for Dr. Aklog of 150% of base salary through the end of the term.
- Additional Benefits: Dr. Aklog receives a $3,300 monthly allowance for transportation and club memberships. Both executives are eligible for up to 12 months of COBRA health coverage upon qualifying termination.
- Restrictive Covenants: Non-competition periods were adjusted to one year generally (two years for change of control), with specific increases for Dr. Aklog and decreases for Mr. McGrath compared to prior terms.
Outlook, Risks, and Unusual Items
Product Development: The company issued a press release on March 20, 2019, providing an update on certain product developments (furnished under Item 7.01 but not deemed "filed" for Section 18 purposes).
Unusual Item - Debt Conversion: The voluntary reduction of the convertible note conversion price is a significant event designed to facilitate equity conversion. This action introduces potential dilution of up to 1,000,000 shares if the holder exercises the option during the 21-day window.
Risks: The filing notes that the restricted stock grants are subject to forfeiture if employment terminates prior to vesting, except in cases of "good reason" or change of control.
Investor Verification Checklist
- Verify the current market price of Pavmed common stock to assess the immediate dilution impact of the reduced conversion price (greater of $1.00 or closing price).
- Review the full text of the Amended and Restated Employment Agreements (Exhibits 10.1 and 10.2) for complete definitions of "good reason" and "change of control."
- Monitor the press release (Exhibit 99.1) for specific details on product development milestones not detailed in the 8-K summary.
- Confirm whether the holder of the $7,750,000 convertible note has elected to convert shares during the 21-day window ending April 9, 2019.